Showing 1 posts of 1 posts found.
Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care